Header image

Quantori blog

March 25, 2024

Approaches to Multi-Omics Data Integration

Natasha Dudek
Natasha Dudek
Senior Data Scientist
Multi-omics analysis is expected to significantly impact biomedical research, leading to a new era of personalized medicine with improved diagnostic and treatment options for patients. This perspective comes from the fact that biological processes, like disease progression, involve complex interactions of biomolecules across various omic layers.

The integrated analysis of multiple omic modalities, such as genomics, transcriptomics, proteomics, metabolomics, epigenomics, and microbiomics, allows scientists to better understand molecular changes between different biological states.

For example, when studying cancer development, combining genomics and metabolomics data can show how gene mutations may correlate with abnormal metabolite production, stimulating tumor growth.


Image Source: Integration strategies of multi-omics data for machine learning analysis

A crucial aspect of multi-omics analysis is integrating data from different omic modalities. Optimal integration empowers multi-omics analysis by aligning the data to underlying assumptions of analytical algorithms. It also captures valuable complementary information between modalities that may amplify salient signals and considers interactions between biomolecules from different omic layers.

For instance, in cancer genetics, combining genomic and transcriptomic data helps match gene expression levels with genetic mutations, providing insights into tumor development.

Multi-omics integration approaches can be loosely categorized by the stage of analysis at which integration is performed. Here, we will focus on early, mixed, intermediate, and late approaches to multi-omics data integration, as defined by Picard et al. (2019).

  1. Early integration. Datasets from all omics modalities are concatenated into a single, large matrix, often followed by the application of dimensionality reduction techniques. The matrix can then be used for downstream analysis, for example for the development of machine learning (ML) models. This approach is simple, fast, and easy. It allows for a variety of downstream analyses that can reveal interactions between biomolecules from different omics layers.

    However, there are several challenges associated with this approach:

    a) the concatenated dataset possesses an extraordinary number of unique features, which exacerbates the curse of dimensionality.
    b) large differences in the number of features per -omics modality can create a learning imbalance where downstream algorithms prioritize one modality over another.
    c) furthermore, distinct and poorly defined data distribution across each modality could violate key assumptions of downstream algorithms and lead to inaccurate or even erroneous.

  2. Mixed integration. Each independent omics data is transformed into a simpler representation before concatenating all representations into a single matrix. Representations can be achieved using techniques such as kernel learning and neural networks (e.g., auto-encoders, graph neural networks, graph convolution networks, restricted Boltzmann machines, etc.).

    Intermediate integration offers a powerful approach for combining information from multiple omics modalities while reducing dimensionality within and heterogeneity between omics datasets. However, this approach may require very large sample sizes in some cases, especially when using deep learning techniques.

  3. Intermediate integration. Multi-omics datasets are integrated without prior omics-specific transformation and with more complex techniques than applying a simple concatenation. These methods often assume that different omics modalities can be decomposed into a common latent space, revealing salient mechanisms underlying a biological process. 
    Methods like non-negative matrix factorization (NMF) and multi-omics factor analysis (MOFA) fall into this category. They tend to be flexible and accommodating of different experimental designs and data inputs, reducing dataset dimensionality and complexity. However, rigorous feature selection and data pre-processing are often required to diminish heterogeneity between datasets and achieve high performance.

  4. Late integration involves analyzing each omics modality separately and then combining the results quantitatively, often through ensemble ML methods such as averaging or majority voting. While this allows one to apply approaches and tools specifically developed for each independent -omics modality, it allows for little to no inference of interactions or complementarities between omics modalities.

Selecting the right data integration method for your multi-omics project lays the foundation for success.  

At Quantori, our team of seasoned bioinformatics experts will guide you towards the most effective analysis strategy for your multi-omics project’s unique needs and help implement that vision. Furthermore, our data landscaping team is adept at augmenting dataset sizes, maximizing the potential of your multi-omics dataset.

Data Science
Scientific Informatics

Do you have any thoughts or questions?

We are looking forward to discussing this article with you. Fill out this form or reach out to contact@quantori.com

This site is protected by reCAPTCHA Enterprise and the Google Privacy Policy and Terms of Service apply

Related Articles

Streamlining AlphaFold for Access and Computational Optimization
Scientific Informatics

Streamlining AlphaFold: Quantori's Solution for Intuitive Access and Computational Optimization

How can users access AlphaFold-like models and seamlessly predict protein structures without the necessity of advanced coding skills? This article explores the Quantori solution that makes this possible.

Read more >
Quantori Drug Discovery
Artificial Intelligence

Revolutionizing Drug Discovery with Multimodal Data and AI: A Deep Dive into Use Cases

In the rapidly evolving landscape of drug discovery, the fusion of multimodal data with artificial intelligence (AI) and machine learning (ML) technologies is setting the stage for groundbreaking advancements. This synergy is not only expediting traditional processes but also paving the way for innovative approaches to complex, man-power intensive challenges. Here, we delve into four transformative use cases, illustrating the power of this integration in revolutionizing drug discovery.

Read more >
Quantori ESG

Embracing ESG Principles as a Stakeholder in Life Science and Healthcare

In today's fast-paced world, sustainability is not just another catchword – it is now one of the main global priorities. Companies across industries are taking a closer look at their practices to ensure they align with ESG - Environmental, Social, and Governance - principles.

Read more >
QFlow: Solution for Managing ML Projects
Data Science

QFlow for Managing Machine Learning Projects in Life Sciences

In recent years, the rapid growth of AI technologies has resulted in more organizations adopting machine learning techniques to solve complex business problems. However, the process of building and deploying ML models at scale can be challenging, involving numerous complex steps such as data preparation, feature engineering, model training, and deployment.

Read more >
searching for medical data
Data Science

How to Dig up More Data for Your Medical Research

No matter how hard you try to progress your research, without enough data, you’ll probably get stuck at some point. This is particularly crucial in the healthcare sector. To extract therapeutic insights from medical records, researchers typically need to work with many hundreds to thousands of patient cases, gathering and processing data from various sources. When the initial evidence at their disposal is limited, the conclusions may become distorted and biased.

Read more >
RWD and RWE Part 2: Challenges and Solutions
Data Science

RWD and RWE Part 2: Challenges and Solutions

We have described RWD and RWD in our previous blog. There is strong promise and increasing use of Real World Evidence to accelerate data-driven decisions, improving not only the clinical trial experience, but healthcare in general. But, can we believe Real World Evidence?

Read more >